Gland Pharma
Market cap ₹53,308 Cr
- P/E
- 43.10
- Day range
- ₹3,208.70 – ₹3,278.00
- 52-week range
- ₹1,573.60 – ₹3,429.00
- Volume
- 2.46 L
- Open
- ₹3,260.00
- Prev close
- ₹3,248.40
Latest results · Q2 FY27(consolidated)Revenue ₹1,834 Cr+23.3%Profit ₹291 Cr+58.3%Margin 15.9%YoY vs the same quarter last year
1 red flag to read up on
- medium
Promoter holding falling
45.75%, down 6.08 pts since 2025-09-30 · 30 Sept 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
GLAND in NSE indices and F&O
Research profile
Composite 70 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.3%
- Graham no.
- ₹1,035.81
- vs Graham
- -67.9%
- ROE ÷ P/B
- 2.0%
- 12-1 mom.
- +61.8%
- Return / vol
- 2.22
- Magic Formula
- #439
- Piotroski
- 6/6
- FCF yield
- 1.0%
Appears in 17 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Gland PharmaGLAND | ₹53,308 Cr | 43.10 | 5.15 | 10.5% | 15.0% | 26.0% | 0.02 | +23.3% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 4d agoHeadlines about Gland Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 42.6
- Price / Book
- 4.99
- ROE (FY26)
- 10.5%
- ROCE (latest year)
- 15%
- Dividend yield
- 0.62%
Moving averages (NSE)
- 20-day
- ₹3,120.44
- Price above
- 50-day
- ₹3,031.27
- Price above
- 200-day
- ₹2,365.51
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- Public
- FII
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 | 1,834 |
| YoY Sales growth | — | — | — | — | -10 | -7 | — | — | — | — | — | — |
| Expenses | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 | 1,077 | 1,138 | 1,173 | 1,260 | 1,230 | 1,311 | 1,350 |
| Operating Profit | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 | 484 |
| OPM % | 23% | 23% | 19% | 21% | 26% | 24% | 24% | 21% | 26% | 29% | 27% | 26% |
| Other Income | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 39 | 111 | 61 | 69 |
| Interest | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 | 7 |
| Depreciation | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 | 115 |
| Profit before tax | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 | 431 |
| Tax % | 32% | 35% | 34% | 36% | 32% | 35% | 31% | 35% | 28% | 28% | 27% | 33% |
| Net Profit | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 | 291 |
| EPS in Rs | ₹11.65 | ₹11.68 | ₹8.73 | ₹9.93 | ₹12.42 | ₹11.32 | ₹13.08 | ₹11.15 | ₹15.87 | ₹22.26 | ₹19.21 | ₹17.62 |
From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+36 days since Mar 2021
-28 days since Mar 2021
+39 days since Mar 2021
-31 days since Mar 2021
-24 days since Mar 2021
Strengths, risks & growth
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 39.1%
Risks
- Stock is trading at 4.99 times its book value
- Promoter holding has decreased over last quarter: -6.02%
- Company has a low return on equity of 9.29% over last 3 years.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +13%
- 3 Years
- +21%
- TTM
- +22%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- +1%
- 3 Years
- +8%
- TTM
- +59%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- -1%
- 3 Years
- +26%
- 1 Year
- +83%
Return on Equity
- 10 Years
- —
- 5 Years
- +11%
- 3 Years
- +9%
- Last Year
- +11%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 51.83% | 51.83% | 51.77% | 45.75% | -6.02 pp |
| FII | 7.58% | 7.29% | 8.74% | 10.36% | +1.62 pp |
| DII | 32.99% | 33.36% | 30.44% | 33.21% | +2.77 pp |
| Government | 0.00% | 0.00% | 0.00% | 0.01% | +0.01 pp |
| Public | 7.62% | 7.52% | 9.06% | 10.68% | +1.62 pp |
Filed with NSE for Sept 2026: promoters 45.75%, public 54.25%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 29.52% (+1.29 pp)- Promoters45.8%
- Foreign institutions10.4%
- Mutual funds29.5%
- Insurance2.4%
- Other domestic institutions1.3%
- Retail4.0%
- Others6.7%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Mid Cap Fund | 3.36% | 1.87% | +0.42 pp |
| Kotak Mid Cap Fund | 2.59% | 2.24% | +2.23 pp |
| SBI Large & Midcap Fund | 1.79% | 2.47% | +0.60 pp |
| Nippon India Growth Mid Cap Fund | 1.59% | 1.77% | +0.39 pp |
| Nippon India Small Cap Fund | 1.01% | 0.74% | +0.16 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 32.3%
- Downside volatility
- 24.4%
- Worst 5% of days
- 2.7%
- Average of that tail
- 3.4%
- Max drawdown (1Y)
- 21.1%
- Below its peak
- 4.6%
Against the market
- Beta vs Nifty 50
- 0.53
- Correlation
- 0.22
- Relative strength (3M)
- +7.1%
- ATR (14)
- 3.2%
Return
- Return 1M
- +6.1%
- Return 3M
- +11.0%
- Return 6M
- +49.8%
- Return 1Y
- +71.7%
- vs 200-day average
- +36.6%
Momentum
- RSI (14)
- 57.3
- MACD histogram
- 10.15
- Stochastic %K
- 52.5
- ADX (14)
- 33.4
- +DI / −DI
- 26.4 / 15.3
- Money flow index
- 83.1
Participation
- Delivery (20d avg)
- 55.7%
- vs its 60-day baseline
- +1.4 pts
- Volume vs 20-day
- -0.5σ
- Close vs day's VWAP
- -0.2%
- 52-week position
- 91 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
6 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- ₹537 Cr
- FCF yield
- 1.0%
- Cash conversion
- 1.00
- Accruals ratio
- -0.000
- Net debt
- -₹3,190 Cr
- Net debt / equity
- -0.30
- EV / sales
- 7.09
- Capex intensity
- 7.7%
- Revenue CAGR
- 18.3%
- Profit CAGR
- 34.4%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
A. JAYATHEERTHA Employees/Designated Employees · Market Sale | Sell | 100 | ₹1.9 L | 11 Feb 2026 |
A. JAYATHEERTHA Employees/Designated Employees · Market Sale | Sell | 306 | ₹5.9 L | 5 Feb 2026 |
P LAKSHMI NARAYANA Employees/Designated Employees · Market Sale | Sell | 800 | ₹14.9 L | 5 Feb 2026 |
P LAKSHMI NARAYANA Employees/Designated Employees · Market Sale | Sell | 300 | ₹5.4 L | 25 Nov 2025 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹20.00
Dividend - Rs 20 Per Sh
11 Aug 2026ex-date - dividend₹18.00
Dividend - Rs 18 Per Share
14 Aug 2025ex-date - dividend₹20.00
Annual General Meeting/Dividend - Rs 20 Per Share
16 Aug 2024ex-date - otherNot available — not reported in this filing
Annual General Meeting
6 Aug 2021ex-date
Company announcements
Certificate under Reg 74(5) of the SEBI (DP) Regulations, 2018
Newspaper Publication regarding the dipatch of Notice of Postal Ballot
Postal Ballot Notice
Resignation of Mr. Wenjie Zhang as a Non-Executive & Non-Independent Director and Appointment of Mr. Xingli Wang as an Additional Director (Non-Executive and Non-Independent Director)
Investment by Gland Pharma Limited in Gland Pharma USA Inc. and Investment by Gland Pharma USA Inc. into Novelstar Pharma Inc.
Outcome of Board Meeting held on October 01, 2026
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Fosun Pharma Industrial Pte Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund
Copy of Newspaper Publication
Acquisition of Gland Pharma USA Inc., a wholly-owned Step down subsidiary from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company
Outcome of Board Meeting
Allotment of 44,193 Equity Shares on exercise of ESOPs
Grant of Stock Options under Gland Pharma Employee Stock Option Scheme, 2025
Board Comments on fines levied by Exchanges
Filed with BSE (scrip 543245); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Aug 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 6 Jun 2018 from fitch
- Rating update · 17 Apr 2017 from fitch
- Rating update · 23 Mar 2016 from fitch
- Rating update · 28 Mar 2013 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 7 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Gland Pharma: common questions
Answered from the figures on this page.